The Chemours Company (NYSE:CC) Stock Rated “Hold” by Sell-Side Brokerages

The Chemours Company (NYSE:CC) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $18.09.

Several research firms have recently commented on CC. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $16.00 price objective on shares of Chemours in a research note on Friday, October 9th. Zacks Research raised Chemours from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 10th. UBS Group cut their price objective on Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. Mizuho reissued a “neutral” rating and issued a $15.00 target price (down from $18.00) on shares of Chemours in a report on Wednesday. Finally, Truist Financial decreased their target price on shares of Chemours from $30.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th.

Insiders Place Their Bets

In other news, insider Calderon Gerardo Familiar acquired 1,935 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Denise Dignam bought 3,378 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the purchase, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. This represents a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 8,663 shares of company stock worth $130,601 over the last three months. 0.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Chemours

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Chemours in the second quarter valued at about $34,000. Allworth Financial LP purchased a new stake in shares of Chemours during the second quarter worth about $51,000. State of Wyoming bought a new stake in Chemours during the 2nd quarter valued at approximately $67,000. Nykredit A S bought a new stake in Chemours during the 2nd quarter valued at approximately $99,000. Finally, Parallel Advisors LLC lifted its holdings in Chemours by 10.9% in the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 527 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities-fraud class action against Chemours and certain executives. The lawsuit covers investors who purchased CC securities from February 20 through August 4, 2026, with a December 7, 2026 deadline to seek lead-plaintiff status. The allegations include misleading statements or omissions about the reliability of the company’s financial guidance, including claims that management overstated aftermarket demand for Opteon refrigerants and failed to account for sales pulled forward by distributor inventory stocking. The allegations have not been proven in court. Chemours investor alert and class-action lawsuit
• Negative Sentiment: The litigation adds potential legal costs, reputational risk and uncertainty around Chemours’ prior guidance and operating disclosures. One notice said CC shares fell 18.63% in a single session, the event underlying the shareholder claims. Chemours shareholder alert
• Negative Sentiment: Mizuho cut its view on Chemours from “strong buy” or “outperform” to “neutral” and lowered its price target to $15. Barclays also rated the shares “hold.” The moves reinforce a more cautious sell-side outlook and may limit near-term buying interest. Mizuho cuts Chemours price target

Chemours Stock Performance

Shares of NYSE:CC traded down $0.20 during midday trading on Friday, hitting $12.71. The company had a trading volume of 2,198,791 shares, compared to its average volume of 2,070,859. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -6.66 and a beta of 1.41. Chemours has a 12-month low of $10.44 and a 12-month high of $28.67. The company has a fifty day moving average of $14.69 and a two-hundred day moving average of $18.87.

Chemours (NYSE:CC) last released its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. Chemours’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the firm posted ($2.54) earnings per share. On average, equities research analysts expect that Chemours will post 0.84 EPS for the current fiscal year.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th were given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Friday, August 14th. Chemours’s dividend payout ratio is presently -18.32%.

About Chemours

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.